Recursion Announces CEO Transition As Najat Khan Succeeds Co-Founder Chris Gibson To Lead Next Phase Of TechBio Growth
Recursion Pharmaceuticals, Inc. Class A +5.93% Pre
Recursion Pharmaceuticals, Inc. Class A RXRX | 3.75 3.83 | +5.93% +2.13% Pre |
Recursion Announces CEO Transition As Najat Khan Succeeds Co-Founder Chris Gibson To Lead Next Phase Of TechBio Growth
